Zegzula H D, Buck D C, Brekke J, Wozney J M, Hollinger J O
Oregon Health Sciences University, Portland 97201-3098, USA.
J Bone Joint Surg Am. 1997 Dec;79(12):1778-90. doi: 10.2106/00004623-199712000-00003.
We examined the effect of rhBMP-2 (recombinant human bone morphogenetic protein-2), delivered in a porous poly(DL-lactic acid) implant, on bone formation in a critical-sized defect in the radial diaphysis in rabbits. A unilateral segmental defect, twenty millimeters long, was created in the radius in ninety-six skeletally mature New Zealand White rabbits. Forty-eight rabbits were evaluated at four weeks and forty-eight, at eight weeks. Six groups were studied at each time-period. The defect was left empty in one group (control), the defect was filled with an autogenous corticocancellous bone graft in one group, and the defect was filled with a porous poly(DL-lactic acid) implant containing zero, seventeen, thirty-five, or seventy micrograms of rhBMP-2 (one group each). Radiographs of the defects were made every two weeks. The percentage of the total area of the defect that was radiopaque was determined with use of computerized radiomorphometry, and this percentage was used as a quantitative measure of the extent of new-bone formation in the defect. There were time and dose-dependent responses to rhBMP-2 for as long as four weeks; thereafter, the effects of seventeen, thirty-five, and seventy micrograms of rhBMP-2 were independent of dose and time (p < or = 0.05). The defects that had been treated with either thirty-five or seventy micrograms of rhBMP-2 had a significantly greater (p < or = 0.05) area of radiopacity than the defects that had been treated with either zero or seventeen micrograms of rhBMP-2. No significant difference could be found between the defects treated with thirty-five or seventy micrograms of rhBMP-2 and the defects filled with an autogenous graft. Healing and bone formation were examined histologically and histomorphometrically as well. At four weeks, polarized light microscopy revealed remnants of poly(DL-lactic acid) only in the defects that had been filled with an implant containing zero micrograms of rhBMP-2. At eight weeks, regardless of the dose of rhBMP-2, poly(DL-lactic acid) was not visible on histological examination. The presence of multinucleated giant cells was the hallmark of the inflammatory response elicited by poly(DL-lactic acid). At four and eight weeks, macrophages and lymphocytes were also present. The intensity of the cellular response at four weeks suggested an inverse relationship between these cells and the dose of rhBMP-2 -- that is, there appeared to be more multinucleated giant cells in defects treated with zero micrograms of rhBMP-2 than in defects treated with seventy micrograms of rhBMP-2. At eight weeks, multinucleated giant cells were rare in the defects treated with seventeen, thirty-five, or seventy micrograms of rhBMP-2. Histomorphometric data at four and eight weeks indicated that the amount of bone formation in the defects treated with seventeen, thirty-five, or seventy micrograms of rhBMP-2 was equivalent to the amount in the defects treated with an autogenous graft and was significantly less (p < or = 0.05) in the untreated defects and the defects treated with zero micrograms of rhBMP-2 (p < or = 0.05). By eight weeks, only thirty-five and seventy micrograms of rhBMP-2 had restored cortices and marrow elements.
我们研究了负载于多孔聚(DL-乳酸)植入物中的重组人骨形态发生蛋白-2(rhBMP-2)对兔桡骨干临界尺寸骨缺损处骨形成的影响。在96只骨骼成熟的新西兰白兔的桡骨上制造了一个长20毫米的单侧节段性缺损。48只兔子在4周时进行评估,48只在8周时进行评估。每个时间段研究6组。一组缺损处不做处理(对照组),一组缺损处填充自体皮质松质骨移植骨,一组缺损处分别填充含0、17、35或70微克rhBMP-2的多孔聚(DL-乳酸)植入物(每组各1组)。每两周对缺损处进行X线摄片。使用计算机化放射形态计量学确定缺损处不透射线的总面积百分比,该百分比用作缺损处新骨形成程度的定量指标。rhBMP-2在长达4周的时间内呈现出时间和剂量依赖性反应;此后,17、35和70微克rhBMP-2的作用与剂量和时间无关(p≤0.05)。用35或70微克rhBMP-2处理的缺损处的不透射线面积显著大于(p≤0.05)用0或17微克rhBMP-2处理的缺损处。用35或70微克rhBMP-2处理的缺损处与填充自体移植骨的缺损处之间未发现显著差异。还通过组织学和组织形态计量学检查了愈合和骨形成情况。在4周时,偏光显微镜检查显示仅在填充含0微克rhBMP-2植入物的缺损处有聚(DL-乳酸)残留。在8周时,无论rhBMP-2的剂量如何,组织学检查均未见到聚(DL-乳酸)。多核巨细胞的存在是聚(DL-乳酸)引发的炎症反应的标志。在4周和8周时,也存在巨噬细胞和淋巴细胞。4周时细胞反应的强度表明这些细胞与rhBMP-2的剂量呈负相关——也就是说,用0微克rhBMP-2处理的缺损处似乎比用70微克rhBMP-2处理的缺损处有更多的多核巨细胞。在8周时,用17、35或70微克rhBMP-2处理的缺损处很少有多核巨细胞。4周和8周时的组织形态计量学数据表明,用17、35或70微克rhBMP-2处理的缺损处的骨形成量与用自体移植骨处理的缺损处相当,且在未处理的缺损处和用0微克rhBMP-2处理的缺损处明显较少(p≤0.05)(p≤0.05)。到8周时,只有35和70微克rhBMP-2恢复了皮质和骨髓成分。